BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance by Ryan J. Sullivan, Keith T. Flaherty

Get full text

Residual Hemothorax after Chest Tube Placement Correlates with Increased Risk of Empyema Following Traumatic Injury by Riyad Karmy-Jones, Michele Holevar, Ryan J Sullivan, Ani Fleisig, Gregory J Jurkovich

Get full text

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I by Xiangyi Kong, Ryan J Sullivan, Caisheng Wu, Lin Zhang, Lin Zhang, Lin Zhang, Yu Jiang

Get full text

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017 by Paolo A. Ascierto, Corrado Caracò, Jeffrey E. Gershenwald, Omid Hamid, Merrick Ross, Ryan J. Sullivan, Igor Puzanov

Get full text

Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma by Cho-Han Chiang, Ryan J Sullivan, Kerry L Reynolds, Soravis Osataphan, Yu Jen Alexander Jan, Aleigha R Lawless

Get full text

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors by Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan, Michael Dougan

Get full text

Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against KitK641E-mutant melanoma by Kishwor Poudel, Zhenyu Ji, Ching-Ni Njauw, Anpuchchelvi Rajadurai, Brijesh Bhayana, Ryan J. Sullivan, Jong Oh Kim, Hensin Tsao

Get full text

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II by Chuqi Lei, Xiangyi Kong, Xiangyi Kong, Ryan J. Sullivan, Caisheng Wu, Caisheng Wu, Dawei Wang, Lin Zhang, Lin Zhang, Lin Zhang

Get full text

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development by Jeffrey Sosman, Elad Sharon, Theresa LaVallee, Hussein A Tawbi, Ryan J Sullivan, Harriet M Kluger, Naiyer A Rizvi, David Feltquate

Get full text

The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 by Paolo A. Ascierto, Renier Brentjens, Samir N. Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov

Get full text

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis by Melissa Lumish, Ryan J. Sullivan, Douglas B. Johnson, Michael Dougan, Anita Giobbie-Hurder, Meghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, Tianqi Chen

Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors by Harriet Kluger, Omid Hamid, Roberta Zappasodi, Michael Hurwitz, Hussein Tawbi, Elad Sharon, Theresa LaVallee, Rebecca A Moss, Justin F Gainor, J Carl Barrett, Ryan J Sullivan

Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies by James L Gulley, Harriet Kluger, Hussein Tawbi, Jeffrey Sosman, Paolo A Ascierto, Michael B Atkins, Nikhil I Khushalani, Douglas B Johnson, Timonthy A Yap, Ryan J Sullivan, David Feltquate

Get full text

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs by Tian Zhang, Patrick M Forde, Elad Sharon, Scot Ebbinghaus, Michael B Atkins, Mark Stewart, Ryan J Sullivan, Elizabeth Barksdale, Wendy Selig, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert

Get full text

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial by Mariano Severgnini, Rizwan Haq, Anita Giobbie-Hurder, Scott J Rodig, Patrick A Ott, Evisa Gjini, Ryan J Sullivan, Donald P Lawrence, Matthew Nazzaro, Kathleen L Pfaff, Jacquelyn O Wolff, Elizabeth I Buchbinder

Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy by Ranee Mehra, Ina Rhee, Naiyer Rizvi, Robert L Ferris, Hussein Tawbi, Matthew D Hellmann, Sarah B Goldberg, Ryan J Sullivan, Helen X Chen, Jong Chul Park, Foluso O Ademuyiwa, Z Alexander Cao

Get full text

Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma by Kuang Du, Shiyou Wei, Zhi Wei, Dennie T. Frederick, Benchun Miao, Tabea Moll, Tian Tian, Eric Sugarman, Dmitry I. Gabrilovich, Ryan J. Sullivan, Lunxu Liu, Keith T. Flaherty, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang

Get full text

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations by Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson

Get full text

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma by Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan

Get full text

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis by Zsofia D. Drobni, Amna Zafar, Leyre Zubiri, Daniel A. Zlotoff, Raza M. Alvi, Charlotte Lee, Sarah Hartmann, Hannah K. Gilman, Alexandra‐Chloe Villani, Anju Nohria, John D. Groarke, Ryan J. Sullivan, Kerry L. Reynolds, Lili Zhang, Tomas G. Neilan

Get full text